Creso Pharma


CV Sciences, Inc.

CVSI


Canadian symbol: CVSI
US symbol: CVSI

Currency in USD

Valuation Measures

Market Cap (intraday) 538.5M
Enterprise Value 342.18M
Trailing P/E N/A
Forward P/E 1-6.01
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)1.58
Price/Book (mrq)3.25
Enterprise Value/Revenue 31.73
Enterprise Value/EBITDA 7-1.94

Trading Information

Stock Price History

Beta (5Y Monthly) 0.31
52-Week Change 35.41%
S&P500 52-Week Change 345.56%
52 Week High 31.2700
52 Week Low 30.3600
50-Day Moving Average 30.4403
200-Day Moving Average 30.5426

Share Statistics

Avg Vol (3 month) 3617.13k
Avg Vol (10 day) 3373.94k
Shares Outstanding 5106.79M
Implied Shares Outstanding 6N/A
Float 103.89M
% Held by Insiders 12.60%
% Held by Institutions 10.02%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2020
Most Recent Quarter (mrq)Dec. 30, 2020

Profitability

Profit Margin -91.22%
Operating Margin (ttm)-92.48%

Management Effectiveness

Return on Assets (ttm)-33.90%
Return on Equity (ttm)-110.43%

Income Statement

Revenue (ttm)24.43M
Revenue Per Share (ttm)0.25
Quarterly Revenue Growth (yoy)-44.30%
Gross Profit (ttm)11.01M
EBITDA -21.72M
Net Income Avi to Common (ttm)-22.28M
Diluted EPS (ttm)-0.2230
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)4.02M
Total Cash Per Share (mrq)0.04
Total Debt (mrq)7.77M
Total Debt/Equity (mrq)69.34
Current Ratio (mrq)1.18
Book Value Per Share (mrq)0.11

Cash Flow Statement

Operating Cash Flow (ttm)-7.3M
Levered Free Cash Flow (ttm)-999.62k

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
CVSI
CV Sciences
2 days ago
CVSI
CV Sciences
2 days ago
CVSI
CV Sciences
1 month ago
CVSI
CV Sciences
1 month ago
CVSI
CV Sciences
2 months ago
CVSI
CV Sciences
3 months ago
CVSI
CV Sciences
3 months ago
CVSI
CV Sciences
4 months ago
CVSI
CV Sciences
5 months ago
CVSI
CV Sciences
6 months ago
CVSI
CV Sciences
6 months ago
CVSI
CV Sciences
6 months ago
CVSI
CV Sciences
6 months ago
CVSI
CV Sciences
6 months ago
CVSI
CV Sciences
7 months ago
CVSI
CV Sciences
8 months ago
CVSI
CV Sciences
8 months ago
CVSI
CV Sciences
8 months ago
CVSI
CV Sciences
8 months ago
CVSI
CV Sciences
8 months ago
CVSI
CV Sciences
9 months ago
CVSI
CV Sciences
9 months ago
CVSI
CV Sciences
9 months ago
CVSI
CV Sciences
9 months ago
CVSI
CV Sciences
10 months ago
CVSI
CV Sciences
10 months ago
CVSI
CV Sciences
11 months ago
CVSI
CV Sciences
11 months ago
CVSI
CV Sciences
11 months ago
CVSI
CV Sciences
12 months ago
CVSI
CV Sciences
12 months ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
1 year ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago
CVSI
CV Sciences
2 years ago

Currency in USD
Earnings EstimateCurrent Qtr. (Mar 2021)Next Qtr. (Jun 2021)Current Year (2021)Next Year (2022)
No. of Analysts4443
Avg. Estimate-0.02-0.03-0.09-0.06
Low Estimate-0.03-0.03-0.1-0.08
High Estimate-0.01-0.02-0.08-0.04
Year Ago EPS-0.05-0.05-0.22-0.09
Revenue EstimateCurrent Qtr. (Mar 2021)Next Qtr. (Jun 2021)Current Year (2021)Next Year (2022)
No. of Analysts4443
Avg. Estimate5.5M5.83M24.76M35.25M
Low Estimate5.15M5.4M23.15M32.48M
High Estimate6.3M6.8M27.2M36.77M
Year Ago Sales8.27MN/A24.43M24.76M
Sales Growth (year/est)-33.50%N/A1.40%42.40%
Earnings History2020-03-302020-06-292020-09-292020-12-30
EPS Est.-0.03-0.03-0.02-0.02
EPS Actual-0.05-0.05-0.03-0.09
Difference-0.02-0.02-0.01-0.07
Surprise %-66.70%-66.70%-50.00%-350.00%
EPS TrendCurrent Qtr. (Mar 2021)Next Qtr. (Jun 2021)Current Year (2021)Next Year (2022)
Current Estimate-0.02-0.03-0.09-0.06
7 Days Ago-0.02-0.03-0.09-0.06
30 Days Ago-0.02-0.02-0.08-0.04
60 Days Ago-0.02-0.01-0.040.01
90 Days Ago-0.02-0.02-0.05-0.03
EPS RevisionsCurrent Qtr. (Mar 2021)Next Qtr. (Jun 2021)Current Year (2021)Next Year (2022)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/A1
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesCVSIIndustrySector(s)S&P 500
Current Qtr.60.00%N/AN/AN/A
Next Qtr.40.00%N/AN/AN/A
Current Year59.10%N/AN/AN/A
Next Year33.30%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
2.60%% of Shares Held by All Insider
0.02%% of Shares Held by Institutions
0.02%% of Float Held by Institutions
4Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Douglass Winthrop Advisors LLC10,000Dec. 30, 20200.01%4,700
Captrust Financial Advisors8,600Dec. 30, 20200.01%4,042
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by CV Sciences, Inc.


CV Sciences, Inc. Announces Launch of PlusCBD™ Calm and Sleep Gummies

CV Sciences, Inc. Announces Launch of PlusCBD™ Calm and Sleep Gummies

SAN DIEGO, May 11, 2021 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced the launch of PlusCBD™ Calm and Sleep: two flavorful gummies that support healthy stress responses and sleep cycles for people getting back to their ... Read More...
CV Sciences, Inc. to Announce First Quarter 2021 Results on May 13, 2021

CV Sciences, Inc. to Announce First Quarter 2021 Results on May 13, 2021

SAN DIEGO, May 06, 2021 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the first quarter ended March 31, 2021, after the stock market closes on Thursday, May 13, 2021... Read More...
CV Sciences and Alkemist Labs Form Partnership to Support the National Institute of Standards and Technology's Cannabis Quality Assurance Program

CV Sciences and Alkemist Labs Form Partnership to Support the National Institute of Standards and Technology’s Cannabis Quality Assurance Program

SAN DIEGO, April 13, 2021 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced an ongoing partnership with Alkemist Labs, an established leader in botanical plant testing, to collaborate with the National Institute of Standard... Read More...
CV Sciences, Inc. Reports Fiscal Year-End 2020 Financial Results

CV Sciences, Inc. Reports Fiscal Year-End 2020 Financial Results

SAN DIEGO, March 18, 2021 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the year ended December 31, 2020.Fiscal 2020 and Recent Operating Highlights Revenue of $24.4 million for fisc... Read More...
CV Sciences, Inc. to Announce Fiscal Year and Fourth Quarter 2020 Results on March 18, 2021

CV Sciences, Inc. to Announce Fiscal Year and Fourth Quarter 2020 Results on March 18, 2021

SAN DIEGO, March 10, 2021 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the fiscal year and fourth quarter ended December 31, 2020, after the stock market closes on ... Read More...
CV Sciences, Inc. Receives Nutritional Outlook's 2020 Best of the Industry Award

CV Sciences, Inc. Receives Nutritional Outlook’s 2020 Best of the Industry Award

SAN DIEGO, Dec. 10, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today that it received Nutritional Outlook’s 2020 Best of the Industry Awards, in the Retail brand/product category. CV Sciences was recognized... Read More...
CV Sciences, Inc. Announces Closing of Committed Equity Financing Transaction

CV Sciences, Inc. Announces Closing of Committed Equity Financing Transaction

SAN DIEGO, Dec. 08, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it has entered into a Common Stock Purchase Agreement with Tumim Stone Capital, LLC (the “Investor”).Pursuant to the Stock Purchase ... Read More...
CV Sciences, Inc. Reports Third Quarter 2020 Financial Results

CV Sciences, Inc. Reports Third Quarter 2020 Financial Results

SAN DIEGO, Nov. 05, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended September 30, 2020.Third Quarter 2020 and Recent Operating HighlightsRevenue of $5.6 million ... Read More...
CV Sciences, Inc. Announces Launch of PlusCBD™ Pet Product Line

CV Sciences, Inc. Announces Launch of PlusCBD™ Pet Product Line

SAN DIEGO, Nov. 04, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced the launch of PlusCBD™ Pet, a full line of hemp extracts formulated exclusively for dogs and cats.Made with the same trusted hemp extracts used in C... Read More...
CV Sciences, Inc. to Announce Third Quarter 2020 Results on November 5, 2020

CV Sciences, Inc. to Announce Third Quarter 2020 Results on November 5, 2020

SAN DIEGO, Oct. 23, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the third quarter ended September 30, 2020, after the stock market closes on Thursday, Novembe... Read More...
CV Sciences, Inc. Announces PlusCBD™ Brand Refresh and New Product Launches

CV Sciences, Inc. Announces PlusCBD™ Brand Refresh and New Product Launches

SAN DIEGO, Oct. 06, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced a comprehensive refresh of its top selling, flagship PlusCBD™ branded product line and the launch of 30+ new PlusCBD™ products over the next 45 days... Read More...
CV Sciences, Inc. Announces Launch of CV™ Defense Daily Immune Support

CV Sciences, Inc. Announces Launch of CV™ Defense Daily Immune Support

SAN DIEGO, Sept. 10, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced its continued expansion into condition specific dietary supplements with the launch of CV™ Defense, the second of several products to be launched u... Read More...
CV Sciences, Inc. Launches New Website Reflecting Core Values and Mission of Improving Quality of Life Through Nature and Science

CV Sciences, Inc. Launches New Website Reflecting Core Values and Mission of Improving Quality of Life Through Nature and Science

SAN DIEGO, Sept. 02, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp-derived cannabidiol (CBD) products, is pleased to announce the launch of its new corporate website (https://www.cvsciences.com/), reflecting the Company’s refreshed brand positioning, core values and... Read More...
CV Sciences, Inc. Experts Contribute to Journal of Dietary Supplements First Special Issue on Cannabinoids

CV Sciences, Inc. Experts Contribute to Journal of Dietary Supplements First Special Issue on Cannabinoids

SAN DIEGO, Aug. 13, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp-derived cannabidiol (CBD) products, is pleased to announce the publication of two papers in the Journal of Dietary Supplements’ first Special Issue on Cannabinoids. In this issue, CV Sciences’ team of... Read More...
CV Sciences, Inc. Reports Second Quarter 2020 Financial Results

CV Sciences, Inc. Reports Second Quarter 2020 Financial Results

SAN DIEGO, Aug. 06, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended June 30, 2020.Second Quarter 2020 and Recent Operating Highlights Revenue of $5.4 million for... Read More...
CV Sciences, Inc. Announces Launch of Happy Lane™ CBD Product Line

CV Sciences, Inc. Announces Launch of Happy Lane™ CBD Product Line

SAN DIEGO, Aug. 05, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced the launch of its new Happy Lane™ CBD product line.Happy Lane™ non-GMO, hemp derived CBD products are manufactured with 0.00% THC (“THC-free”) and f... Read More...
CV Sciences, Inc. Announces Expansion with the Launch of CV™ Acute and New Immunity Product Line

CV Sciences, Inc. Announces Expansion with the Launch of CV™ Acute and New Immunity Product Line

SAN DIEGO, July 29, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced a strategic category expansion into condition specific dietary supplements with the launch of CV™ Acute, the first of several products to be launche... Read More...
CV Sciences, Inc. to Announce Second Quarter 2020 Results on August 6, 2020

CV Sciences, Inc. to Announce Second Quarter 2020 Results on August 6, 2020

SAN DIEGO, July 23, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the second quarter ended June 30, 2020, after the stock market opens on Thursday, August 6, 20... Read More...
CV Sciences, Inc. Announces Publication of Two Research Studies Demonstrating the Safety and Health Benefits of PlusCBD™ Products

CV Sciences, Inc. Announces Publication of Two Research Studies Demonstrating the Safety and Health Benefits of PlusCBD™ Products

SAN DIEGO, June 02, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, is pleased to announce the publication of two research studies demonstrating the safety and health benefits of PlusCBD™ products.  Both studies were publ... Read More...
CV Sciences, Inc. Announces Plan to Adjourn Annual Meeting of Stockholders to June 16, 2020

CV Sciences, Inc. Announces Plan to Adjourn Annual Meeting of Stockholders to June 16, 2020

SAN DIEGO, May 20, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will adjourn its 2020 Annual Meeting of Stockholders to June 16, 2020 in order to allow additional time to solicit proxies as a result of maili... Read More...
CV Sciences, Inc. Receives Formal Notice of Patent Issuance from USPTO for Proprietary Cannabidiol (CBD) and Nicotine Formulation for Treating Smokeless Tobacco Addiction

CV Sciences, Inc. Receives Formal Notice of Patent Issuance from USPTO for Proprietary Cannabidiol (CBD) and Nicotine Formulation for Treating Smokeless Tobacco Addiction

SAN DIEGO, May 20, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that on May 19, 2020, the Company received its formal Notice of Issuance from the U.S. Patent and Trademark Office (USPTO) for its patent ... Read More...
CV Sciences, Inc. Reports First Quarter 2020 Financial Results

CV Sciences, Inc. Reports First Quarter 2020 Financial Results

SAN DIEGO, May 08, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2020.First Quarter 2020 and Recent Operating Highlights Revenue of $8.3 million for ... Read More...
CV Sciences, Inc. to Announce First Quarter 2019 Results on May 8, 2020

CV Sciences, Inc. to Announce First Quarter 2019 Results on May 8, 2020

SAN DIEGO, April 30, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the quarter ended March 31, 2020, before the stock market opens on Friday, May 8, 2020. The C... Read More...
CV Sciences, Inc. Announces Filing of Form S-3 Shelf Registration Statement

CV Sciences, Inc. Announces Filing of Form S-3 Shelf Registration Statement

SAN DIEGO, April 22, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it had filed a Shelf Registration Statement on Form S-3 with the Securities and Exchange Commission (“SEC”) on April 21, 2020.At pr... Read More...
CV Sciences, Inc. Receives Notice of Patent Allowance from USPTO for Proprietary Cannabidiol (CBD) and Nicotine Formulation for Treating Smokeless Tobacco Addiction

CV Sciences, Inc. Receives Notice of Patent Allowance from USPTO for Proprietary Cannabidiol (CBD) and Nicotine Formulation for Treating Smokeless Tobacco Addiction

SAN DIEGO, April 06, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that on April 3, 2020, the Company learned that it will be receiving a Notice of Allowance from the U.S. Patent and Trademark Office (US... Read More...
CV Sciences, Inc. Reports Fiscal Year-End 2019 Financial Results

CV Sciences, Inc. Reports Fiscal Year-End 2019 Financial Results

SAN DIEGO, March 16, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the year ended December 31, 2019.Fiscal 2019 and Recent Operating Highlights Revenue of $53.7 million for fisc... Read More...
Cv Sciences, Inc. Reschedules Full Year 2019 Results Conference Call To March 16, 2020

Cv Sciences, Inc. Reschedules Full Year 2019 Results Conference Call To March 16, 2020

SAN DIEGO, March 10, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will now release financial results for the year ended December 31, 2019, after the stock market closes on Monday, March 16, 2020... Read More...
CV Sciences, Inc. to Announce Full Year 2019 Results on March 10, 2020

CV Sciences, Inc. to Announce Full Year 2019 Results on March 10, 2020

SAN DIEGO, Feb. 26, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the year ended December 31, 2019, after the stock market closes on Tuesday, March 10, 2020. Th... Read More...
CV Sciences, Inc. Launches Updated +PlusCBD™ Oil Website to Enhance User Experience and Drive Increased E-Commerce Sales

CV Sciences, Inc. Launches Updated +PlusCBD™ Oil Website to Enhance User Experience and Drive Increased E-Commerce Sales

Refreshed Website Guides Visitors on their Hemp CBD Journey with Multimedia Educational Resources, In-Depth Product Information and Improved Shopping Tools Company Well Positioned to Drive Rapid E-Commerce Channel Growth SAN DIEGO, Jan. 23, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preem... Read More...
Farmers Insurance Open Selects +PlusCBD™ Oil as Their First-Ever CBD Sponsor

Farmers Insurance Open Selects +PlusCBD™ Oil as Their First-Ever CBD Sponsor

SAN DIEGO, Jan. 21, 2020 -- CV Sciences, Inc (OTCQB: CVSI) (the “Company”, “we” or “our”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products through its brand PlusCBD Oil™, is the first-ever CBD sponsor of the Farmers Insurance Open. The Farmers Insurance Open is a PGA Golf tournament taking place Thursday, Jan. 23... Read More...
CV Sciences, Inc. to Participate at the 22nd Annual ICR Conference

CV Sciences, Inc. to Participate at the 22nd Annual ICR Conference

SAN DIEGO, Jan. 08, 2020 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that Joseph Dowling, the Company's Chief Executive Officer and Joerg Grasser, Chief Financial Officer, will present and meet with investo... Read More...
Tim Hitchman, PhD, Joins CV Sciences, Inc. as Director of Operations

Tim Hitchman, PhD, Joins CV Sciences, Inc. as Director of Operations

Hitchman Brings Deep Experience in Product Development, Commercialization and OperationsSAN DIEGO, Dec. 17, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that Tim Hitchman, PhD, has joined the Company as... Read More...
CV Sciences to Present at the 12th Annual LD Micro Main Event

CV Sciences to Present at the 12th Annual LD Micro Main Event

SAN DIEGO, Dec. 03, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that Joseph Dowling, the Company’s Chief Executive Officer, will present at the 12th Annual LD Micro Main Event. The conference is being ... Read More...
CV Sciences, Inc. Announces New Distribution Partnership With Southeastern Grocers

CV Sciences, Inc. Announces New Distribution Partnership With Southeastern Grocers

New Partnership with Southeastern Grocers Launches PlusCBD™ Oil Topical Products and Dietary Supplements at 115 Winn-Dixie Stores in Florida and 37 BI-LO Stores in South CarolinaSAN DIEGO, Nov. 11, 2019 -- CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidi... Read More...
CV Sciences, Inc. Reports Third Quarter 2019 Financial Results

CV Sciences, Inc. Reports Third Quarter 2019 Financial Results

Increased Retail Distribution by Over 800 StoresSAN DIEGO, Nov. 05, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended September 30, 2019. Third Quarter 2019 and Re... Read More...
CV Sciences, Inc. Applauds USDA's Establishment of the U.S. Domestic Hemp Production Program

CV Sciences, Inc. Applauds USDA’s Establishment of the U.S. Domestic Hemp Production Program

Program Creates a Consistent Regulatory Framework for Hemp Production Throughout the United StatesSAN DIEGO, Oct. 30, 2019 -- CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, is pleased to announce its support of the U.S. Department of ... Read More...
CV Sciences, Inc. Appoints Beth Altman to its Board of Directors

CV Sciences, Inc. Appoints Beth Altman to its Board of Directors

SAN DIEGO, Oct. 29, 2019 -- CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the appointment of Beth Altman to its Board of Directors effective October 24, 2019.“Beth is a highly experienced financial executive and board... Read More...
CV Sciences, Inc. to Sponsor 26th Annual HIACON Conference in Charlotte, North Carolina on Nov. 1-4, 2019

CV Sciences, Inc. to Sponsor 26th Annual HIACON Conference in Charlotte, North Carolina on Nov. 1-4, 2019

SAN DIEGO, Oct. 24, 2019 -- CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today its title sponsorship of the Hemp Industries Association® (HIA®) annual conference and tradeshow, HIACON. This year’s conference will be held N... Read More...
CV Sciences, Inc. to Announce Third Quarter 2019 Results on November 5, 2019

CV Sciences, Inc. to Announce Third Quarter 2019 Results on November 5, 2019

SAN DIEGO, Oct. 23, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for its third quarter 2019 ended September 30, 2019, after the stock market closes on Tuesday, Nov... Read More...
CV Sciences, Inc. Appoints Dr. Paul Blake to its Board of Directors

CV Sciences, Inc. Appoints Dr. Paul Blake to its Board of Directors

SAN DIEGO, Oct. 22, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the appointment of Dr. Paul Blake to its Board of Directors effective October 21, 2019.“We are very pleased to have Dr. Blake join our Bo... Read More...
CV Sciences, Inc. Announces Expanded Distribution Partnership With The Vitamin Shoppe

CV Sciences, Inc. Announces Expanded Distribution Partnership With The Vitamin Shoppe

Partnership Broadens Distribution of PlusCBD™ Oil Products to More Than 500 The Vitamin Shoppe LocationsSAN DIEGO, Oct. 17, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, is pleased to announce further expansion of ... Read More...
CV Sciences, Inc. Announces Distribution Partnership With Harris Teeter

CV Sciences, Inc. Announces Distribution Partnership With Harris Teeter

Partnership Broadens Distribution of PlusCBD™ Oil Products to 150 Harris Teeter LocationsSAN DIEGO, Oct. 01, 2019 --  CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, is pleased to announce further expansion of its industry-d... Read More...
CV Sciences Applauds House Passage of the SAFE Banking Act of 2019

CV Sciences Applauds House Passage of the SAFE Banking Act of 2019

The SAFE Banking Act Provides the Cannabis Industry Access to Banking and Financial ServicesSAN DIEGO, Sept. 30, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announces its full support of the House of Representatives’ ... Read More...
CV Sciences, Inc. Launches Seven New Body Care Hemp CBD Products at Natural Products Expo East

CV Sciences, Inc. Launches Seven New Body Care Hemp CBD Products at Natural Products Expo East

SAN DIEGO, Sept. 24, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, has announced the expansion of its industry-dominating brand, PlusCBD™ Oil, with the launch of seven new body care products at Natural Products Expo Eas... Read More...
CV Sciences, Inc. Announces Plans to File Request For Continued Examination of Its US Patent Application

CV Sciences, Inc. Announces Plans to File Request For Continued Examination of Its US Patent Application

SAN DIEGO, Sept. 19, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its intention to file for a Request of Continued Examination (“RCE”) of its patent application No. 15/426,617 with the US Patent Tradema... Read More...
CV Sciences, Inc. Wins 2019 NEXTY Award

CV Sciences, Inc. Wins 2019 NEXTY Award

Company’s industry-dominating hemp extract brand, PlusCBD Oil™, wins Consumer Choice Award at Natural Products Expo EastSAN DIEGO, Sept. 17, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today that it rec... Read More...
Pro Mountain Biker Cam McCaul Partners with PlusCBD™ Oil

Pro Mountain Biker Cam McCaul Partners with PlusCBD™ Oil

SAN DIEGO, Sept. 11, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company,” “CV Sciences,” “our” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, is pleased to announce they have partnered with professional mountain biker Cam McCaul to endorse industry-dominating PlusCBD™ Oil brand.McCaul, one of the le... Read More...
CV Sciences, Inc Appoints Terri Funk Graham to Board of Directors

CV Sciences, Inc Appoints Terri Funk Graham to Board of Directors

Graham Brings Extensive Fortune 1000 Experience Serving on Boards of Directors and in Senior Leadership RolesSAN DIEGO, Aug. 27, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that Terri Funk Graham has b... Read More...
Coming Soon.

Delayed data (1h)


Share this page